Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β

Sandhya Subramanian, Micah Tovey, Michael Afentoulis, Aric Krogstad, Arthur Vandenbark, Halina Offner

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We previously demonstrated the therapeutic effects of ethinyl estradiol (EE), an orally active estrogen and a component of birth control pills, in encephalitogenic autoimmune encephalomyelitis (EAE). In this study, we report the effectiveness of EE in treating collagen-induced arthritis (CIA) induced with bovine type II collagen (bCII) in DBA/1LacJ mice, a CIA susceptible strain. Both low and high doses of EE notably suppressed clinical and histological signs of CIA in a dose-dependent manner compared to vehicle-treated controls. Oral treatment with EE decreased proliferation and secretion of pro-inflammatory factors, TNF-α IFN-γ, MCP-1 and IL-6 by bCII peptide-specific T cells, production of bCII-specific IgG2a antibodies, and mRNA for cytokines, chemokines and chemokine receptors in joint tissue. This is the first report demonstrating effective treatment of joint inflammation and clinical signs of CIA with orally administered ethinyl estradiol, thus supporting its possible clinical use for treating rheumatoid arthritis in humans.

Original languageEnglish (US)
Pages (from-to)162-172
Number of pages11
JournalClinical Immunology
Volume115
Issue number2
DOIs
StatePublished - May 2005

Fingerprint

Inbred DBA Mouse
Ethinyl Estradiol
Experimental Arthritis
Interleukin-1
Joints
Peptide T
Encephalomyelitis
Cytokine Receptors
Collagen Type II
Chemokine Receptors
Therapeutic Uses
Contraception
Chemokines
Interleukin-6
Rheumatoid Arthritis
Estrogens
Inflammation
T-Lymphocytes
Messenger RNA
Antibodies

Keywords

  • Collagen-induced arthritis
  • Cytokines
  • Ethinyl estradiol
  • Oral therapy
  • Regulation of T cells and antibodies

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β. / Subramanian, Sandhya; Tovey, Micah; Afentoulis, Michael; Krogstad, Aric; Vandenbark, Arthur; Offner, Halina.

In: Clinical Immunology, Vol. 115, No. 2, 05.2005, p. 162-172.

Research output: Contribution to journalArticle

Subramanian, Sandhya ; Tovey, Micah ; Afentoulis, Michael ; Krogstad, Aric ; Vandenbark, Arthur ; Offner, Halina. / Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β. In: Clinical Immunology. 2005 ; Vol. 115, No. 2. pp. 162-172.
@article{a5260b0f5a75494ba57e6884a655adac,
title = "Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β",
abstract = "We previously demonstrated the therapeutic effects of ethinyl estradiol (EE), an orally active estrogen and a component of birth control pills, in encephalitogenic autoimmune encephalomyelitis (EAE). In this study, we report the effectiveness of EE in treating collagen-induced arthritis (CIA) induced with bovine type II collagen (bCII) in DBA/1LacJ mice, a CIA susceptible strain. Both low and high doses of EE notably suppressed clinical and histological signs of CIA in a dose-dependent manner compared to vehicle-treated controls. Oral treatment with EE decreased proliferation and secretion of pro-inflammatory factors, TNF-α IFN-γ, MCP-1 and IL-6 by bCII peptide-specific T cells, production of bCII-specific IgG2a antibodies, and mRNA for cytokines, chemokines and chemokine receptors in joint tissue. This is the first report demonstrating effective treatment of joint inflammation and clinical signs of CIA with orally administered ethinyl estradiol, thus supporting its possible clinical use for treating rheumatoid arthritis in humans.",
keywords = "Collagen-induced arthritis, Cytokines, Ethinyl estradiol, Oral therapy, Regulation of T cells and antibodies",
author = "Sandhya Subramanian and Micah Tovey and Michael Afentoulis and Aric Krogstad and Arthur Vandenbark and Halina Offner",
year = "2005",
month = "5",
doi = "10.1016/j.clim.2005.01.006",
language = "English (US)",
volume = "115",
pages = "162--172",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β

AU - Subramanian, Sandhya

AU - Tovey, Micah

AU - Afentoulis, Michael

AU - Krogstad, Aric

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 2005/5

Y1 - 2005/5

N2 - We previously demonstrated the therapeutic effects of ethinyl estradiol (EE), an orally active estrogen and a component of birth control pills, in encephalitogenic autoimmune encephalomyelitis (EAE). In this study, we report the effectiveness of EE in treating collagen-induced arthritis (CIA) induced with bovine type II collagen (bCII) in DBA/1LacJ mice, a CIA susceptible strain. Both low and high doses of EE notably suppressed clinical and histological signs of CIA in a dose-dependent manner compared to vehicle-treated controls. Oral treatment with EE decreased proliferation and secretion of pro-inflammatory factors, TNF-α IFN-γ, MCP-1 and IL-6 by bCII peptide-specific T cells, production of bCII-specific IgG2a antibodies, and mRNA for cytokines, chemokines and chemokine receptors in joint tissue. This is the first report demonstrating effective treatment of joint inflammation and clinical signs of CIA with orally administered ethinyl estradiol, thus supporting its possible clinical use for treating rheumatoid arthritis in humans.

AB - We previously demonstrated the therapeutic effects of ethinyl estradiol (EE), an orally active estrogen and a component of birth control pills, in encephalitogenic autoimmune encephalomyelitis (EAE). In this study, we report the effectiveness of EE in treating collagen-induced arthritis (CIA) induced with bovine type II collagen (bCII) in DBA/1LacJ mice, a CIA susceptible strain. Both low and high doses of EE notably suppressed clinical and histological signs of CIA in a dose-dependent manner compared to vehicle-treated controls. Oral treatment with EE decreased proliferation and secretion of pro-inflammatory factors, TNF-α IFN-γ, MCP-1 and IL-6 by bCII peptide-specific T cells, production of bCII-specific IgG2a antibodies, and mRNA for cytokines, chemokines and chemokine receptors in joint tissue. This is the first report demonstrating effective treatment of joint inflammation and clinical signs of CIA with orally administered ethinyl estradiol, thus supporting its possible clinical use for treating rheumatoid arthritis in humans.

KW - Collagen-induced arthritis

KW - Cytokines

KW - Ethinyl estradiol

KW - Oral therapy

KW - Regulation of T cells and antibodies

UR - http://www.scopus.com/inward/record.url?scp=18844411612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844411612&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2005.01.006

DO - 10.1016/j.clim.2005.01.006

M3 - Article

VL - 115

SP - 162

EP - 172

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -